Resultats de la cerca - Jonathan Polikoff

  • Mostrar 1 - 20 resultats de 20
Refinar resultats
  1. 1
    Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades

    Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades per Reina Haque, Syed A. Ahmed, Galina Inzhakova, Jiaxiao Shi, Chantal Avila, Jonathan Polikoff, Leslie Bernstein, Shelley M. Enger, Michael F. Press

    Publicat 2012
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

    Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study per Pier Luigi Zinzani, Julie M. Vose, M. S. Czuczman, Craig B. Reeder, Corinne Haïoun, Jonathan Polikoff, Hervé Tilly, L. Zhang, K. Prandi, J. Li, Thomas E. Witzig

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

    Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant Prostate Can... per Andrew J. Armstrong, Michael Häggman, Walter M. Stadler, Jeffrey R. Gingrich, Vasily J. Assikis, Jonathan Polikoff, J.‐E. Damber, Laurence Belkoff, Örjan Nordle, G. Forsberg, Michael A. Carducci, Роберто Пили

    Publicat 2013
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

    An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma per Thomas E. Witzig, Julie M. Vose, Pier Luigi Zinzani, Craig B. Reeder, Rena Buckstein, Jonathan Polikoff, Réda Bouabdallah, Corinne Haïoun, Hervé Tilly, Pi Guo, Dennis Pietronigro, A. Ervin-Haynes, M. S. Czuczman

    Publicat 2011
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

    Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treat... per Eric Van Cutsem, Josep Tabernero, Radek Lakomý, Hans Prenen, Jana Prausová, Teresa Macarulla, Paul Ruff, Guy A. Van Hazel, Vladimir Moiseyenko, David Ferry, Joe McKendrick, Jonathan Polikoff, Alexia Tellier, R Castan, Carmen J. Allegra

    Publicat 2012
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

    ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab fo... per Bruce E. Johnson, Fairooz F. Kabbinavar, Louis Fehrenbacher, John D. Hainsworth, Saifuddin M. Kasubhai, Bruce Kressel, Chin-Yu Lin, Thomas Marsland, Taral Patel, Jonathan Polikoff, Mark A. Rubin, Leonard A. White, James Chih‐Hsin Yang, Chris Bowden, Vincent A. Miller

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

    Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial per Ronald P. DeMatteo, Karla V. Ballman, Cristina R. Antonescu, Robert G. Maki, Peter W. T. Pisters, George D. Demetri, Martin E. Blackstein, Charles D. Blanke, Margaret von Mehren, Murray F. Brennan, Shreyaskumar Patel, Martin D. McCarter, Jonathan Polikoff, Benjamin Tan, Kouros Owzar

    Publicat 2009
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Menstrual History and Quality-of-Life Outcomes in Women With Node-Positive Breast Cancer Treated With Adjuvant Therapy on the NSABP B-30 Trial

    Menstrual History and Quality-of-Life Outcomes in Women With Node-Positive Breast Cancer Treated With Adjuvant Therapy on the NSABP B-30 Trial per Patricia A. Ganz, Stephanie R. Land, Charles E. Geyer, Reena S. Cecchini, Joseph P. Costantino, Eduardo R. Pajon, Louis Fehrenbacher, James N. Atkins, Jonathan Polikoff, Victor G. Vogel, John K. Erban, Robert B. Livingston, Edith A. Perez, Eleftherios P. Mamounas, Norman Wolmark, Sandra M. Swain

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer

    Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer per Sandra M. Swain, Jong‐Hyeon Jeong, Charles E. Geyer, Joseph P. Costantino, Eduardo R. Pajon, Louis Fehrenbacher, James N. Atkins, Jonathan Polikoff, Victor G. Vogel, John K. Erban, Priya Rastogi, Robert B. Livingston, Edith A. Perez, Eleftherios P. Mamounas, Stephanie R. Land, Patricia A. Ganz, Norman Wolmark

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC

    Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC per Fabrice Barlési, K. Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, David R. Gandara, C.H. Barrios, D.S. Chen, Phoebe Chu He, Marcin Kowanetz, M. Ballinger, Daniel Waterkamp, A. Sandler, Achim Rittmeyer

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    PL04a.02: OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses

    PL04a.02: OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses per Shirish M. Gadgeel, Fortunato Ciardiello, Achim Rittmeyer, Fabrice Barlési, Diego Cortinovis, Carlos H. Barrios, Toyoaki Hida, Keunchil Park, Dariusz M. Kowalski, Manuel Cobo, Joseph L. Leach, Jonathan Polikoff, Christina Matheny, Pei He, Marcin Kowanetz, Daniel Chen, Daniel Waterkamp, Marcus Ballinger, Alan Sandler, David R. Gandara, Joachim von Pawel

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

    NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and Wit... per Louis Fehrenbacher, Reena S. Cecchini, Charles E. Geyer, Priya Rastogi, Joseph P. Costantino, James N. Atkins, John Crown, Jonathan Polikoff, Jean-François Boileau, Louise Provencher, Christopher Stokoe, Timothy D. Moore, André Robidoux, Patrick J. Flynn, Virginia F. Borges, Kathy S. Albain, Sandra M. Swain, Soonmyung Paik, Eleftherios P. Mamounas, Norman Wolmark

    Publicat 2019
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43

    Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43 per Kalliopi P. Siziopikou, Stewart Anderson, Melody A. Cobleigh, Thomas B. Julian, Douglas W. Arthur, Ping Zheng, Eleftherios P. Mamounas, Eduardo R. Pajon, Robert J. Behrens, Janice F. Eakle, Nick C. Leasure, James N. Atkins, Jonathan Polikoff, Thomas E. Seay, Worta J. McCaskill-Stevens, Rachel Rabinovitch, Joseph P. Costantino, Norman Wolmark

    Publicat 2013
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial

    Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial per Sandra M. Swain, Gong Tang, Charles E. Geyer, Priya Rastogi, James N. Atkins, Paul Donnellan, Louis Fehrenbacher, Catherine A. Azar, André Robidoux, Jonathan Polikoff, Adam Brufsky, David D. Biggs, Edward A. Levine, John L. Zapas, Louise Provencher, Donald W. Northfelt, Soonmyung Paik, Joseph P. Costantino, Eleftherios P. Mamounas, Norman Wolmark

    Publicat 2013
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme

    Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme per Albert Lai, Anh Tran, Phioanh L. Nghiemphu, Whitney B. Pope, Orestes E. Solis, Michael T. Selch, Emese Filka, William H. Yong, Paul S. Mischel, Linda M. Liau, Surasak Phuphanich, Keith L. Black, Scott Peak, Richard M. Green, Cynthia E. Spier, Tatjana Kolevska, Jonathan Polikoff, Louis Fehrenbacher, Robert M. Elashoff, Timothy F. Cloughesy

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

    Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzu... per Edward H. Romond, Jong‐Hyeon Jeong, Priya Rastogi, Sandra M. Swain, Charles E. Geyer, Michael S. Ewer, Vikas Rathi, Louis Fehrenbacher, Adam Brufsky, Catherine A. Azar, Patrick J. Flynn, John L. Zapas, Jonathan Polikoff, Howard M. Gross, David D. Biggs, James N. Atkins, Elizabeth Tan-Chiu, Ping Zheng, Greg Yothers, Eleftherios P. Mamounas, Norman Wolmark

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2

    Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin an... per Patricia A. Ganz, Edward H. Romond, Reena S. Cecchini, Priya Rastogi, Charles E. Geyer, Sandra M. Swain, Jong‐Hyeon Jeong, Louis Fehrenbacher, Howard M. Gross, Adam Brufsky, Patrick J. Flynn, Tanya A. Wahl, Thomas E. Seay, James L. Wade, David D. Biggs, James N. Atkins, Jonathan Polikoff, John L. Zapas, Eleftherios P. Mamounas, Norman Wolmark

    Publicat 2017
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

    Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1 per Matthew R. Smith, Johann S. de Bono, Cora N. Sternberg, Sylvestre Le Moulec, Stéphane Oudard, Ugo De Giorgi, Michael Krainer, Andries M. Bergman, Wolfgang Hoelzer, Ronald de Wit, Martin Bögemann, Fred Saad, Giorgio Cruciani, Antoine Thiery-Vuillemin, Susan Feyerabend, Kurt Miller, Nadine Houédé, Syed A. Hussain, Elaine T. Lam, Jonathan Polikoff, Arnulf Stenzl, Paul N. Mainwaring, David A. Ramies, Colin Hessel, Aaron Weitzman, Karim Fizazi

    Publicat 2016
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

    Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial per Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara

    Publicat 2016
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

    Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE per Eleftherios P. Mamounas, Michael Untch, Max S. Mano, Chiun‐Sheng Huang, Charles E. Geyer, Gϋnter von Minckwitz, Norman Wolmark, Xavier Pivot, Sherko Küemmel, Michael P. DiGiovanna, Bella Kaufman, G. Kunz, Alison Conlin, Juan Carlos Alcedo, Thorsten Kuehn, Irene Wapnir, Andrea Fontana, John Hackmann, Jonathan Polikoff, Mahasti Saghatchian, Adam Brufsky, Youngsen Yang, Martina Zimovjanová, Thomas Boulet, H. Liu, David Tesarowski, Lisa H. Lam, Chunyan Song, Melanie C. Smitt, Sibylle Loibl

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: